KLOX Technologies announces European CE mark approval for acute and chronic wounds treatment - KLOX plans to launch its product LumiHeal™ in 2015

LAVAL, QC, Nov. 6, 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the "Company") is pleased to announce that it has received CE mark approval in Europe for its topical photo-converter gel, LumiHeal^TM, as a Class IIb Medical Device for the treatment of acute and chronic wounds. This gel is part of KLOX's innovative, non-invasive, and patented BioPhotonic platform which is designed to promote healing of wounds while addressing bacterial contamination. KLOX plans to independently commercialize LumiHeal™ in Europe in 2015.

"KLOX's global strategic partnerships in dermatology have enabled us to solidify our position as a leading specialty pharma company. With this regulatory approval in hand, we intend to focus our financial and human resources on independently commercializing and realizing the value of our promising wound care franchise as part of a multi-billion dollar global market. We plan to initially launch LumiHeal^TM in Europe and subsequently leverage the CE mark in other geographies where the CE mark is recognized," stated Dr. Lise Hébert, President and CEO of KLOX. "Our BioPhotonic platform is truly innovative in the way it harnesses light and oxygen to accelerate healing, while carrying bactericidal properties. Accordingly, we believe that our treatment will represent a much-awaited solution for patients suffering from acute and chronic wounds while also helping to reduce the cost of treatments which currently represents a large financial burden to the global healthcare system," she concluded.

"Chronic wounds are frequently challenging to treat for physicians and are both debilitating and painful for patients. LumiHeal™ is positioned to become a leading and effective treatment to optimize the patients' own physiological responses to injured tissues thus promoting healing," added Dr. Andreas Nikolis, Plastic Surgeon, Division of Plastic Surgery, Université de Montréal.

About chronic wounds
A chronic wound is a wound that fails to progress through the various phases of wound healing. Chronic wounds generally result from the presence of several intrinsic and extrinsic factors and, as such, are often complicated, debilitating and painful. They can be lengthy and expensive to treat, and can lead to serious complications such as severe infections and amputations.   Any wound has the potential to become chronic, however such wounds most commonly arise from one of three aetiologies: diabetes (diabetic foot ulcers), venous insufficiency (venous leg ulcers) and pressure (pressure ulcers) and as such create significant and costly challenges for healthcare systems. The cost of lower extremity ulcers is estimated to be greater than the annual cost of treating colorectal and breast cancer (Barshes, et al, 2013) and the relative five-year mortality rate after limb amputation is 68%. To put this into perspective, it is estimated that in the United States alone, chronic wounds are estimated to affect 6.5 million patients, with over $25 billion spent annually on treatment.

It is documented that there are 20 million chronic wounds globally and, while several treatment options currently exist, efficacy cannot be guaranteed. While some wounds can be brought to a favorable state using existing therapies, many currently continue to remain and require complex, lengthy and expensive treatment in order to ensure wound closure if they indeed close.

About KLOX's wound care treatment
The KLOX BioPhotonic Systems are innovative and non-invasive treatment solutions that harness the power of light and oxygen to treat serious skin and tissue disorders. The proprietary KLOX BioPhotonic System for wounds is comprised of a multi-LED light and a topical photo-converter gel that is applied on the open wound. The illumination of the gel with the multi-LED light permits the synergistic effects of oxidants and photons (fluorescence), which are produced by the photo-converting gel in specific ratios. The treatment duration lasts only a few minutes and is repeated twice a week until the wound is healed. This technology is non-abrasive, non-thermal, and has been reported to be comfortable for the patient.

About KLOX Technologies
KLOX is a leading life sciences specialty pharma company based in Laval, Quebec, Canada. KLOX is focused on the development and commercialization its non-invasive BioPhotonic platform, with a focus on the dermatological, wound care and oral health markets.

For further information on KLOX, please visit the Company's website www.kloxtechnologies.com or follow us on Twitter @KLOXTech.

Forward Looking Statements
Certain statements contained in this press release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond KLOX Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which KLOX Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from KLOX Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.

SOURCE: KLOX Technologies Inc.

Amélie Forcier, NATIONAL Public Relations, [phone]